Department of surgery, Sahlgrenska University Hospital
Gothenburg, 413 45, Sweden
NCT Number: NCT00681486
The study is designed to evaluate whether ghrelin treatment can improve appetite in weight losing cancer patients.
Looking for future studies?
Notify MeRandomized study with follow up evaluations each month until preterminal state. Cancer patients will be randomised to either high dose or low dose of active treatment given as daily injection.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
High dose of ghrelin given as subcutaneous injection once a day for the duration of 8 weeks.
Time frame: June 2008
Looking for future studies?
Notify MeGöteborg University
Other
Ghrelin - A Possible Opportunity to Improve Appetite, Nutritional State, Metabolic Integrity and Physical Functioning in Cancer Patients With Progressive Weight Loss
Acronym: Phase 3
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03952624
CFS, Cancer
Bethesda, Maryland, United States
View Trial DetailsNCT07837440
Anxiety Disorders, Behavior
Kāshān, Isfahan, Iran
View Trial DetailsNCT03668223
Anxiety, Anxiety Disorders
Los Angeles, California, United States
View Trial DetailsNCT04442425
Cancer, Neoplasms
Bethesda, Maryland, United States
View Trial Details